Loading...
Please wait, while we are loading the content...
Similar Documents
Clinicopathological features and survival in EBV-positive diffuse large B-cell lymphoma not otherwise specified
| Content Provider | Scilit |
|---|---|
| Author | Bourbon, Estelle Maucort-Boulch, Delphine Fontaine, Juliette Mauduit, Claire Sesques, Pierre Safar, Violaine Ferrant, Emmanuelle Golfier, Camille Ghergus, Dana Karlin, Lionel Lazareth, Anne Bouafia, Fadhela Pica, Gian Matteo Orsini-Piocelle, Frédérique Rocher, Clément Gros, François-Xavier Parrens, Marie Dony, Arthur Rossi, Cédric Ghesquières, Hervé Bachy, Emmanuel Traverse-Glehen, Alexandra Sarkozy, Clémentine |
| Copyright Year | 2021 |
| Description | In this retrospective study, we report 70 cases of Epstein-Barr virus (EBV)+ diffuse large B-cell lymphoma not otherwise specified (DLBCL-NOS) among 1696 DLBCL-NOS cases diagnosed between 2006 and 2019 (prevalence of 4.1%). At diagnosis, median age was 68.5 years; 79% of the cases presented with an advanced-stage disease (III-IV), 48% with extranodal lesions, and 14% with an hemophagocytic lymphohistiocytosis (HLH) (8 at diagnosis and 1 on therapy). A total of 46 cases presented a polymorphic pattern, and 21 were monomorphic. All had a non-germinal center B phenotype, with the majority of tumor cells expressing CD30 and programmed death ligand 1 (98% and 95%, respectively). Type II and III EBV latency was seen in 88% and 12% of the cases, respectively. Patients were treated with immunochemotherapy (59%) or chemotherapy (22%), and 19% received palliative care due to advanced age and altered performance status. After a median follow-up of 48 months, progression-free survival (PFS) and overall survival (OS) at 5 years were 52.7% and 54.8%, respectively. Older age (>50 years) and HLH were associated with shorter PFS and OS in multivariate analysis (PFS: hazard ratio [HR], 14.01; 95% confidence interval [CI], 2.34-83.97; and HR, 5.78; 95% CI, 2.35-14.23; OS: HR, 12.41; 95% CI, 1.65-93.53; and HR, 6.09; 95% CI, 2.42-15.30, respectively). Finally, using a control cohort of 425 EBV− DLBCL-NOS, EBV positivity was associated with a shorter OS outcome within patients >50 years (5-year OS, 53% [95% CI, 38.2-74] vs 60.8% [95% CI, 55.4-69.3], P = .038), but not in younger patients. |
| Related Links | https://ashpublications.org/bloodadvances/article-pdf/5/16/3227/1819008/advancesadv2021004515.pdf |
| Ending Page | 3239 |
| Page Count | 13 |
| Starting Page | 3227 |
| DOI | 10.1182/bloodadvances.2021004515 |
| Journal | Blood advances |
| Issue Number | 16 |
| Volume Number | 5 |
| Language | English |
| Publisher | American Society of Hematology |
| Publisher Date | 2021-08-24 |
| Access Restriction | Open |
| Subject Keyword | Hematology Survival Ebv Dlbcl Nos Pfs Lymphoma Specified Shorter Journal: Blood advances (Vol- 126, Issue- 16) |
| Content Type | Text |
| Resource Type | Article |
